| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry
|
Sonomoto, Koshiro
|
|
|
11 |
3 |
p. 709-736
|
artikel
|
| 2 |
A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers
|
Han, Lyrialle W.
|
|
|
11 |
3 |
p. 755-771
|
artikel
|
| 3 |
Assessment of Patient–Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study
|
Perrotta, Fabio Massimo
|
|
|
11 |
3 |
p. 553-562
|
artikel
|
| 4 |
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
|
Baker, Joshua F.
|
|
|
11 |
3 |
p. 841-853
|
artikel
|
| 5 |
Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
|
Lubrano, Ennio
|
|
|
11 |
3 |
p. 663-674
|
artikel
|
| 6 |
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
|
Warren, Richard B.
|
|
|
11 |
3 |
p. 829-839
|
artikel
|
| 7 |
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
|
Mease, Philip J.
|
|
|
11 |
3 |
p. 817-828
|
artikel
|
| 8 |
Current Use and Barriers to Point-of-Care Ultrasound in Rheumatology: A National Survey of VA Medical Centers
|
Iqbal, Ayesha
|
|
|
11 |
3 |
p. 855-867
|
artikel
|
| 9 |
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
|
Östör, Andrew
|
|
|
11 |
3 |
p. 633-648
|
artikel
|
| 10 |
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial
|
Kristensen, Lars Erik
|
|
|
11 |
3 |
p. 617-632
|
artikel
|
| 11 |
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
|
Kivitz, Alan J.
|
|
|
11 |
3 |
p. 675-689
|
artikel
|
| 12 |
Elevating the Standard of Care for Patients with Axial Spondyloarthritis: ‘Calls to Action’ from Rheumacensus, a Multistakeholder Pan-European Initiative
|
Phoka, Andri
|
|
|
11 |
3 |
p. 773-794
|
artikel
|
| 13 |
Elevating the Standard of Care for Patients with Psoriatic Arthritis: ‘Calls to Action’ from a Multistakeholder Pan-European Initiative
|
Verbinnen, Iris
|
|
|
11 |
3 |
p. 795-815
|
artikel
|
| 14 |
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial
|
de Vlam, Kurt
|
|
|
11 |
3 |
p. 691-707
|
artikel
|
| 15 |
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
|
Fleischmann, Roy
|
|
|
11 |
3 |
p. 599-615
|
artikel
|
| 16 |
Long-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany
|
Lynen, Nils A.
|
|
|
11 |
3 |
p. 649-662
|
artikel
|
| 17 |
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
|
Baraliakos, Xenofon
|
|
|
11 |
3 |
p. 583-597
|
artikel
|
| 18 |
Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study
|
Frade-Sosa, Beatriz
|
|
|
11 |
3 |
p. 501-521
|
artikel
|
| 19 |
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis
|
Brossard, Patrick
|
|
|
11 |
3 |
p. 869-880
|
artikel
|
| 20 |
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
|
Bessette, Louis
|
|
|
11 |
3 |
p. 563-582
|
artikel
|
| 21 |
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
|
Kristensen, Lars Erik
|
|
|
11 |
3 |
p. 487-499
|
artikel
|
| 22 |
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
|
Burmester, Gerd R.
|
|
|
11 |
3 |
p. 737-753
|
artikel
|
| 23 |
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
|
Ruscitti, Piero
|
|
|
11 |
3 |
p. 539-551
|
artikel
|
| 24 |
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
|
Jin, Ran
|
|
|
11 |
3 |
p. 523-537
|
artikel
|
Tijdschrift beschrijving